So we are speaking about $6-$9 billion modestly, not peak, and it would not be unreasonable to then see the bidding start 5X Revenues, say $30 - $45billion for an independent company over the next 24 months. All the doubters are similar when JAZZ was trading below $8 a share. JAZZ takeout is probably 20X that very same $8. I would never say never to NVAX going over $100 pre-buyout if they remain independent in 4 years.
And who can doubt growth will be not just intensify internally but other innovators will want to team up and be acquired by NVAX furthering thier world growth in pharmaceutical revenues.